Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

(2016) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary

(2015) Hideki Takeuchi et al.   International Journal of Clinical Oncology

Improved Anti-Emetic Efficacy of 5-HT3Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter

(2014) Teuta Zoto et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Association of ABCB1 Polymorphisms with the Antiemetic Efficacy of Granisetron plus Dexamethasone in Breast Cancer Patients

(2013) Daiki Tsuji et al.   Drug Metabolism and Pharmacokinetics

Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

(2011) D. A. Perwitasari et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting

(2010) E. M. Choi et al.   ANAESTHESIA

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

(2009) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-Induced Nausea and Vomiting

(2008) Lisa Lohr   CANCER JOURNAL

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE